Santhera grants Agamree rights to Nxera for DMD

Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea. Agamree is a new drug that operates by attaching to the same receptor as glucocorticoids while altering its downstream activity. The agreement involves the development, manufacturing and commercialisation of Agamree and is valued at up to $205m plus royalties. Under the deal, Santhera will be eligib ...